Dual carrier immunogenic construct

Details Dual carrier immunogenic construct Dual carrier immunogenic construct

1995-03-13

1996-12-17

Housel, James C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

4242011, 4242021, 4242031, 4242801, 42419611, 42419711, 4242561, 4242441, 4242361, 4242401, 4242391, 530403, 530806, A61K 39385, A61K 3902, A61K 3912, A61K 39116

Patent

active

055851002

ABSTRACT:
A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, treatment, and prevention of diseases.

REFERENCES:
patent: 4169137 (1979-09-01), Hirschfeld et al.
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4415552 (1983-11-01), Dieiner et al.
patent: 4434150 (1984-02-01), Azad et al.
patent: 4619828 (1986-10-01), Gordon
patent: 4644059 (1987-02-01), Gordon
patent: 4703039 (1987-10-01), Hawiger et al.
patent: 4713240 (1987-12-01), Wilkins et al.
patent: 4748111 (1988-05-01), Dattagupta et al.
patent: 4769237 (1988-09-01), Bittle et al.
patent: 4780312 (1988-10-01), Talwar
patent: 4824775 (1989-04-01), Dattagupta et al.
patent: 4830852 (1989-05-01), Marburg et al.
patent: 4863729 (1989-09-01), Zuckerkandl
patent: 4894229 (1990-01-01), Polson et al.
patent: 5085862 (1992-02-01), Klein et al.
patent: 5126131 (1992-06-01), Dintzis et al.
patent: 5153312 (1992-10-01), Porro
Baltz et al (1977) Eur. J. Immurol 7:218-222.
Hosokawa (1979) Immurology 38:291-299.
Tadakuma et al. (1982) J. Immurol. 128:206-210.
Watanabe et al (1983) Abstract Only Cell Immunol 79:345-357.
Yaffe et al (1983) J Immunol 130:632-635.
Geerligs et al (1988) J. Immunol Meth 106:239-244.
Dintzis et al (1989) J Immunol 143:1239-1244.
Boslego et al "Gonorrhea Vaccines" in Vaccines & Immunotherapy Cryz S. J ed. Pergamon Press, New York, 1991 pp. 211-223.
Kallings et al, Lancet I: 955-960, 1988.
Butcher G. A, Parisitology 98:315-327, 1989.
Patarroyo et al, Nature 328:629-632, 1987.
Inman J. K., J Immunol. 114(2): 704-709, 1975.
Stites et al, eds Basic & Clinical Immunology, Appleton & Lang Norwalk, CT 6th Ed. p. 703 1987.
Stedman's Medical Dictionary, Williams & Wilkins, Baltimore 24th Ed., 1982, p. 1526.
Mitani et al., Infection and Immunity, "Immunoglobulin E-Suppressing and Immunoglobulin G-Enhancing Tetanus Toxoid Prepared by Conjugation with Pullulan," vol. 36, No. 3, pp. 971-976 (Jun. 1982).
Beuvery et al., "Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate," J. Infect. 6:247-255 (1983).
Ahmad et al., The Journal of Immunology, 136:1223-1226, Restoration of In Vitro Responsiveness of XID B Cells to TNP-Ficoll by 8-Mercaptoguanosine (Feb. 1986).
Dancey et al., The Journal of Immunology, 122:638-642, Immunogenicity of Liposomal Model Membrances Sensitized with Dinitrophenylated Phosphati-dylethanolamine Derivatives Containing Different Length Spacers (Feb. 1979).
Anderson et al., The Journal of Immunology, 142:2464-2468, Effect of Oligo-saccharide Chain Length, Exposed Terminal Group, and Hapten Loading on the Antibody Response of Human Adults and Infants to Vaccines . . . (Apr. 1989).
Dick et al., Cruse J. M., Lewis R. E. (eds), Contributions to Microbiology and Immunology, Conjugate Vaccines, 10:48-114, Glycoconjugates of Bacterial Carbohydrate Antigens (1989).
Mosier et al., The Journal of Experimental Medicine, 139:1354-1360, Cellular Requirements for the Primary In Vitro Antibody Response to DNP-Ficoll, (1974).
Mosier et al., The Journal of Immunology, 119:1874-1878, The Ontogeny of Thymic Independent Antibody Responses In Vitro in Normal Mice and Mice With an X-Linked B Cell Defect (Dec. 1977).
Mond, J. J., Immunological Reviews, 64:99-115, Use of the T Lymphocyte Regulated Type 2 Antigens for the Analysis of Responsiveness of Lyb5 and Lyb5 B Lymphocytes to T Lymphocyte Derived Factors (1982).
Mond et al., The Journal of Immunology, 123:239-245, Analysis of B Cell Activation Requirements with TNP-Conjugated Polyacrylamide Beads (Jul. 1979).
Dintzis et al., The Journal of Immunology, 143:1239-1244, The Immunogeni-city of Soluble Haptenated Polymers is Determined by Molecular Mass and Hapten Valence (Aug. 1989).
Brunswick et al., The Journal of Immunology, 140:3364-3372, Picogram Quantities of Anti-Ig Antibodies Coupled to Dextran Induce B Cell Prolifer-ation (May 1988).

Affiliated with

Also associated with

Rating

Dual carrier immunogenic construct does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dual carrier immunogenic construct, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dual carrier immunogenic construct will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1989301